In 2016, Brasil et al. ([@R1]), on the basis of a large number of suspected (n = 364) and laboratory-confirmed (n = 119) cases, reported the first Zika virus outbreak in Rio de Janeiro, with peak transmission in May 2015. Reports confirming Zika virus infection by reverse transcription PCR (RT-PCR) indicated the virus was present earlier in Rio Grande do Norte, Brazil, in October 2014 ([@R2]) and in Bahia, Brazil, in May 2015 ([@R3]). These cases were thought to be the first to occur in humans in Brazil and to correspond with the first occurrences of presumptive vectorborne transmission of Zika virus in the continental Americas.

By August 2015, Zika virus infection had been confirmed in 13 states of Brazil (Bahia, Rio Grande do Norte, São Paulo, Alagoas, Pará, Roraima, Rio de Janeiro, Maranhão, Pernambuco, Ceará, Paraíba, Paraná, and Piauí), some of which were located \>2,500 miles apart ([@R4]). Because Zika virus circulation can occur simultaneously with dengue virus (DENV) in regions plagued by *Aedes aegypti* mosquitoes, we used frozen serum samples previously collected during a DENV type 4 (DENV-4) outbreak to investigate whether co-circulation might have been occurring before reported cases.

We evaluated 210 samples collected from patients (median age 36.6 years) with acute febrile syndrome who visited an acute healthcare facility in Tijuca, a middle-class district in the northern zone of Rio de Janeiro, Brazil, during a DENV-4 outbreak occurring March‒May 2013. All samples tested negative for DENV RNA by RT-PCR and DENV nonstructural protein 1 by Platelia Dengue NS1 Ag ELISA (BioRad Laboratories, Marnes-la-Coquette, France) ([@R5]).

In June 2017, we performed a molecular test to rapidly detect Zika virus in previously frozen acute-phase samples. We extracted viral RNA from 200-µL samples by using the QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer's instructions. We performed quantitative RT-PCR (qRT-PCR) with the QuantiNova Probe RT-PCR Kit (QIAGEN) in a Rotor-Gene Q Sequence Detection System (QIAGEN) using 25-µL reaction mixtures containing 5 µL of RNA template. We used primers, probes, and cycling conditions for Zika virus detection recommended by the Centers for Disease Control and Prevention ([@R6]). Samples suspected positive (defined as having a cycle threshold \<38) were retested in triplicate, and consistently positive samples were confirmed by repeating RNA extraction and qRT-PCR in duplicate.

Of the 210 samples, 21 tested positive by qRT-PCR and were thus suspected positive for Zika virus; 4 of 21 tested positive for Zika virus RNA in triplicate qRT-PCR reactions. However, 1 of the 4 also tested positive by Panbio Dengue IgM Capture ELISA (Standard Diagnostics Inc., Yongin, South Korea). We confirmed that the other 3 samples (2 from men and 1 from a woman) were positive for Zika virus genome after repetition of RNA extraction and qRT-PCR.

Zika virus‒positive patients were young (18, 25, and 26 years of age), lived in Tijuca, had low-grade fever (1‒2 days) during acute disease, and had no underlying conditions. Their travel histories were not available. All patients reported prostration, myalgia, arthralgia, headache, retro-orbital pain, and nausea ([Table](#T1){ref-type="table"}). None reported rash or hemorrhages. Hematocrit levels were 40%‒45%, platelet counts 2.19‒3.53 × 10^5^/µL, and leukocyte counts 4.4‒19.8 × 10^3^ cells/µL.

###### Distribution of clinical signs and symptoms among 3 patients retrospectively identified as having Zika virus infection, Rio de Janeiro, Brazil, 2013\*

  No. patients, sign or symptom   Patient A   Patient B   Patient C
  ------------------------------- ----------- ----------- -----------
  3 patients                                              
  Arthralgia†                     Yes         Yes         Yes
  Fever†, no. days                Yes, 1      Yes, 2      Yes, 1
  Headache                        Yes         Yes         Yes
  Myalgia                         Yes         Yes         Yes
  Nausea                          Yes         Yes         Yes
  Prostration                     Yes         Yes         Yes
  Retroorbital pain               Yes         Yes         Yes
  2 patients                                              
  Adenomegaly                     Yes         Yes         No
  Chills                          Yes         No          Yes
  Dizziness                       Yes         Yes         No
  Low back pain                   No          Yes         Yes
  Taste alteration                Yes         Yes         No
  Vomiting                        Yes         No          Yes
  1 patient                                               
  Anorexia                        No          No          Yes
  Cold extremities                Yes         No          No
  Cough                           Yes         No          No
  Dyspnea                         No          Yes         No
  Eye congestion                  No          Yes         No
  Eye redness perception†         No          Yes         No
  Hemoconcentration               No          No          Yes
  Hoarseness                      No          Yes         No
  Leukopenia                      No          Yes         No
  Oropharyngeal pain              Yes         No          No
  Otalgia                         No          Yes         No
  Pruritus                        No          Yes         No
  Thready pulse                   Yes         No          No

\*No patients had exanthema. †Signs and symptoms considered in Brazilian Ministry of Health's definition for suspected Zika virus infection (<http://portalsaude.saude.gov.br/index.php/descricao-da-doenca-zika>).

Zika virus dissemination beyond Asia and Africa occurred after the 2007 epidemic in Micronesia ([@R6]) and, in particular, after the 2013--2014 outbreak in French Polynesia, which involved a large number of symptomatic patients and patients with severe disease, with some having neurologic syndromes ([@R7]). Brasil et al. ([@R1]) stated that the phylogenetic analysis of cases in Rio de Janeiro supports the hypothesis that Zika virus was introduced into the city in August 2014, possibly during the International Va'a Federation World Sprint Championship canoe race, which included teams from 4 Zika virus‒endemic countries of the Pacific region. Faria et al. ([@R7]) used viral genome analyses of the southeastern Asia and Pacific founder lineage to estimate that Zika virus was present in Brazil by February 2014; these authors also suggested that the northeast region of Brazil was the initial virus dissemination point. Massad et al. ([@R8]) used mathematical models and concluded that Zika virus was most likely introduced into Brazil by infected travelers arriving during October 2013‒March 2014.

However, our findings suggest that Zika virus had already been circulating in Rio de Janeiro since April 2013, consistent with the report by Metsky et al. ([@R9]) stating that Zika virus had been circulating undetected in multiple regions for many months before the initial case reports. This view is also supported by entomological data from Ayllón et al. ([@R10]), who used a surveillance program involving field-trapped mosquitoes to perform genetic analyses of mosquitoborne viruses found in Rio de Janeiro during February 2014‒June 2016. Their results suggest that Zika virus was probably already in circulation in Rio de Janeiro during May--November 2013, introduced multiple times from different in-country sources, and that the virus was introduced into the Americas via Brazil during October 2012‒May 2013 ([@R10]).
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